Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

MXC.L (MXC) Share News

123456

IN BRIEF: MGC Pharmaceuticals appoints Yifat Steuer deputy CEO

4th Oct 2022 11:07

MGC Pharmaceuticals - Perth, Australia-based medicinal cannabis company - Appoints Yifat Steuer as the company's new chief operating officer and deputy chief executive officer. Steuer has worked across a range of pharmaceutical companies, including Johnson & Johnson, GSK PLC as well as with start-ups. The company said that Brett Mitchell has moved from executive chair to non-executive chair "to be more in line with corporate structuring of UK listed companies." Read More

UK shareholder meetings calendar - next 7 days

28th Sep 2022 16:05

Read More

MGC Pharmaceuticals shares down on advertising fine in Australia

28th Sep 2022 12:23

(Alliance News) - MGC Pharmaceuticals Ltd on Wednesday said it faces 23 infringement notices worth AUD306,960, around GBP185,470, for contravening therapeutic goods advertising laws. Read More

IN BRIEF: MGC Pharma receives USD550,000 more from Mercer Street

23rd Sep 2022 13:43

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives a further USD550,000 under the USD10 million financing agreement signed with Mercer Street Global Opportunity Fund LLC, a fund managed by Mercer Street Capital Partner. Under the terms of the agreement, announced in July, MGC Pharma will now issue Mercer 605,000 convertible notes with a face value of USD1.00 each. The funds received will be used to fund MGC's ongoing operations such as clinical trials. Read More

IN BRIEF: MGC notes "encouraging" results from CimetrA study

21st Sep 2022 17:53

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says interim results from the CimetrA study show no significant Covid-19 related complications, compared to 63% of placebo group who reported adverse events related to Covid-19 symptoms. The study had 16 participants with Covid-19. No patients from either drug study group showed any Covid-19 related adverse events, it noted. It also notes improvements in multiple parameters measuring the patient's clinical condition, such as respiratory rate and oxygen saturation, when compared to placebo. Read More

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

1st Sep 2022 17:52

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

25th Aug 2022 16:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

18th Aug 2022 11:57

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters. Read More

MGC shares rise on USD1 million order for ArtemiC

17th Aug 2022 11:12

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC. Read More

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

15th Aug 2022 17:31

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration. Read More

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

5th Aug 2022 14:58

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

29th Jul 2022 19:36

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

28th Jul 2022 20:08

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

25th Jul 2022 21:53

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts. Read More

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

14th Jul 2022 21:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

8th Jul 2022 14:19

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19. Read More

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

6th Jul 2022 20:08

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says. Read More

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

27th Jun 2022 20:27

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms. Read More

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

24th Jun 2022 10:13

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA. Read More

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

16th Jun 2022 13:43

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death. Read More

123456
FTSE 100 Latest
Value8,275.66
Change0.00